Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
Zevra Therapeutics submitted U.S. Patent No. 11,707,456 for its lead drug MIPLYFFA to the FDA for listing in the Orange Book. The patent expires on November 19, 2041, extending the period of regulatory exclusivity and delaying potential generic entry for the treatment of Niemann-Pick disease type C.
Key figures
- Drug Name
- MIPLYFFA (arimoclomol)
- Patent number
- 11,707,456
- Patent expiration date
- November 19, 2041
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.